Window Therapeutics develops targeted cancer therapeutics using proprietary Bottle-brush-Analogue-Macromonomer (BAM) technology to enhance drug efficacy while significantly reducing systemic toxicity. This platform augments the activity of various drug classes, enabling deeper penetration into diseased tissue for localized treatment. The technology aims to widen the therapeutic window, offering clinicians more effective and safer treatment regimens for cancer patients.
Funding
$7.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NSFounders
Product
Problem
Many cancer therapies exhibit significant toxicity to healthy cells, resulting in a narrow therapeutic window where the drug is effective without causing severe adverse effects. This limitation restricts the dosage and effectiveness of treatments, especially for vulnerable patients with advanced cancers or other health issues.
Solution
Window Therapeutics is developing cancer therapeutics using its proprietary Bottle-brush-Analogue-Macromonomer (BAM) technology to widen the therapeutic window of a wide range of drug classes. The BAM technology enhances the activity of cancer drugs while simultaneously diminishing their systemic toxicity. This targeted approach allows drugs to achieve their full therapeutic potential, offering clinicians and patients more effective therapeutic regimens from the outset of treatment. The BAM technology facilitates the development of breakthrough cancer therapeutics designed to penetrate diseased tissue and exert activity specifically against cancer cells, sparing healthy ones.
Target Audience
The primary target audience includes clinicians and patients seeking more effective and safer cancer treatment options, as well as pharmaceutical companies looking to optimize and de-risk their drug development pipelines.
Features
- Bottle-brush-Analogue-Macromonomer (BAM) technology platform for re-engineering molecularly targeted therapies.
- Development of new combination therapies and safer, more focused immuno-therapeutics.
- BAM technology enables the creation of Biologic-Brush Conjugates.
- Optimization and acceleration of pre-clinical, early or late-stage drug candidates.
- Rehabilitation of drug candidates that have encountered mid- to late-stage clinical trial failure.
- Efficient life-cycle management for marketed drugs through new chemical entity (NCE) designations.